Predxbio develops platforms that integrate unbiased spatial analytics with explainable AI to generate novel insights in spatially intelligent biology. These solutions accelerate drug discovery by identifying new cell types, biomarkers, and targets with high confidence. The technology also enables precise patient stratification for clinical trials and the creation of highly predictive companion diagnostics.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional pathology analysis relies on manual review of whole slide images, which can be subjective and time-consuming. Identifying subtle cellular patterns and interactions within the tumor microenvironment is challenging, hindering the discovery of novel biomarkers and effective patient stratification for immunotherapy.
Solution
PredxBio offers an AI-powered spatial analytics platform that analyzes whole slide images of pathology samples to identify novel cell types and biomarkers. By applying unbiased spatial analysis and explainable AI, the platform uncovers previously unseen relationships between cells and their functional states. This technology enables more precise patient stratification for clinical trials, facilitates the development of highly predictive companion diagnostics, and ultimately personalizes therapeutic options for immunotherapy cancer patients. The platform's data-driven approach accelerates drug discovery by identifying novel targets and biomarkers, while also optimizing clinical workflows through increased efficiency and accuracy.
Target Audience
The primary users are clinicians and researchers in drug discovery and clinical development, specifically those focused on immunotherapy for cancer patients.
Features
- Unbiased spatial analytics to identify novel cell types, biomarkers, and targets
- Explainable AI to provide insights into cellular interactions and functional states
- Automated analysis of whole slide images, reducing manual review time
- Patient stratification for clinical trials with high precision
- Development of highly predictive companion diagnostics and prognostics
- Personalized adjuvant therapy options based on individual patient profiles
- Identification of sub-populations of patient response to immunotherapy with >90% confidence